

THAT WHICH IS CLAIMED:

1. A child resistant blister package comprising:
a film having a surface wherein a plurality of cavities are formed therein
5 containing at least one medicament;
a cover sheet which overlies said cavities and is bonded to said film; and
a wall structure raised above the surface of said film which extends
throughout said film forming an interior region such that the plurality of cavities are
enclosed within the interior region.
10
2. The blister package according to Claim 1, wherein said plurality
of cavities are present in at least one column.
3. The blister package according to Claim 1, wherein said plurality
15 of cavities are present in two columns.
4. The blister package according to Claim 1, wherein said plurality
of cavities are present in four columns.
- 20 5. The blister package according to Claim 1, wherein said cover
sheet comprises a material selected from the group consisting of cellulose, polymer,
metal, and combinations thereof.
6. The blister package according to Claim 5, the cover sheet is present in
25 the form of a metallic foil layer and wherein the metallic foil layer comprises
aluminum.
7. The blister package according to Claim 6, wherein the cover sheet
further comprises a second layer attached to the bottom of said metallic foil layer.
30
8. The blister package according to Claim 7, wherein the second
layer comprises paperboard, and wherein the cover sheet is present as a laminate.

9. The blister package according to Claim 1, wherein said film comprises a material selected from the group consisting of polyvinyl chloride,
5 polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

10. The blister package according to Claim 1, wherein said wall structure comprises a material selected from the group consisting of polyvinyl
10 chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

11. The blister package according to Claim 1, wherein the at least one medicament is selected from the group consisting of antibiotics, antivirals, H₂-
15 receptor antagonists, 5HT₁ agonists, 5HT₃ antagonists, COX2-inhibitors, medicaments used in treating psychiatric conditions, medicaments used in treating metabolic conditions, anticancer medicaments, medicaments used in treating neurological conditions, medicaments used in treating cardiovascular conditions, non-steroidal anti-inflammatories medicaments, medicaments used in treating
20 Central Nervous System conditions, medicaments employed in treating Hepatitis B and C, and combinations thereof.

12. The blister package according to Claim 1, wherein the at least one
25 medicament comprises an antiviral.

13. The blister package according to Claim 12, wherein the antiviral is a nucleoside reverse transcriptase inhibitor.

30 14. The blister package according to Claim 1, wherein the at least one medicament comprises lamivudine, zidovudine, viramune, and combinations thereof.

15. The blister package according to Claim 1, wherein a first pharmaceutical formulation comprises lamivudine and zidovudine and a second pharmaceutical formulation comprises viramune and wherein the first
5 pharmaceutical formulation and the second pharmaceutical formulation are present in discrete blisters.

16. The blister package according to Claim 15, wherein the blisters are present in at least two columns, and wherein the first column contains blisters
10 comprising the first pharmaceutical formulation and the second column contains blisters comprising the second pharmaceutical formulation.

17. The blister package according to Claim 1, wherein the package is present as a compliance pack.
15

18. The blister package according to Claim 1, wherein the package is present as a sample pack.

19. The blister package according to Claim 1, wherein the medicament is
20 present in an oral pharmaceutical formulation.

20. The blister package according to Claim 19, wherein the oral pharmaceutical formulation is present in a unit dosage form selected from the group consisting of a tablet, a pill, a capsule, a lozenge, and combinations thereof.
25

21. A child resistant blister package comprising:
a film having an outer edge and a surface wherein a plurality of cavities are formed therein containing at least one medicament, said plurality of cavities being present in at least one column;
30 a cover sheet which overlies said cavities and is bonded to said film, said cover sheet including at least one layer comprising a metallic foil; and
a wall structure raised above the surface of said film which extends

throughout said film forming an interior region which encloses said plurality of cavities therein.

22. The blister package according to Claim 21, wherein said
5 plurality of cavities are present in two columns.

23. The blister package according to Claim 21, wherein said plurality of cavities are present in four columns.

10 24. The blister package according to Claim 21, wherein said cover sheet is present as a laminate.

25. The blister package according to Claim 21, wherein said film comprises a material selected from the group consisting of polyvinyl chloride,
15 polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

26. The blister package according to Claim 21, wherein said wall structure comprises a material selected from the group consisting of polyvinyl
20 chloride, polyvinylidene chloride, polypropylene, polyethylene, polychlorotrifluoroethylene, and combinations thereof.

27. The blister package according to Claim 21, wherein the at least one medicament is selected from the group consisting of antibiotics, antivirals, H₂-
25 receptor antagonists, 5HT₁ agonists, 5HT₃ antagonists, COX2-inhibitors, medicaments used in treating psychiatric conditions, medicaments used in treating metabolic conditions, anticancer medicaments, medicaments used in treating neurological conditions, medicaments used in treating cardiovascular conditions, non-steroidal anti-inflammatories medicaments, medicaments used in treating
30 Central Nervous System conditions, medicaments employed in treating Hepatitis B and C, and combinations thereof.

28. The blister package according to Claim 21, wherein the at least one medicament comprises an antiviral.

5 29. The blister package according to Claim 28, wherein the antiviral is a nucleoside reverse transcriptase inhibitor.

30. The blister package according to Claim 21, wherein the at least one medicament comprises lamivudine, zidovudine, viramune, and combinations
10 thereof.

31. The blister package according to Claim 21, wherein a first pharmaceutical formulation comprises lamivudine and zidovudine and a second pharmaceutical formulation comprises viramune and wherein the first
15 pharmaceutical formulation and the second pharmaceutical formulation are present in discrete blisters.

32. The blister package according to Claim 31, wherein the blisters are present in at least two columns, and wherein the first column contains blisters
20 comprising the first pharmaceutical formulation and the second column contains blisters comprising the second pharmaceutical formulation.

33. The blister package according to Claim 21, wherein the package is present as a compliance pack.
25

34. The blister package according to Claim 21, wherein the package is present as a sample pack.

35. The blister package according to Claim 21, wherein the medicament is
30 present in an oral pharmaceutical formulation.

36. The blister package according to Claim 35, wherein the oral

pharmaceutical formulation is present in a unit dosage form selected from the group consisting of a tablet, a pill, a capsule, a lozenge, and combinations thereof.

5